Portable ultra-low-field MR brain imaging provides affordable and accessible technology that may help physicians monitor ARIA and Alzheimer's disease progression in diverse professional care settings.
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop system—today announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer's Association International Conference, July 28–August 1 in Philadelphia.
These presentations, submitted by clinicians from Washington University in St. Louis, Massachusetts General Hospital, and Yale University, highlight promising applications of portable ultra-low-field MR imaging within the Alzheimer's care continuum.